Positron Emission Tomography (PET) News and Research

RSS

Piramal to present data on several molecular imaging compounds at SNM annual meeting

Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited, will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13.

10 Jun 2012

Cardinal Health to launch new technology enhancements at SNM annual meeting

At the Society of Nuclear Medicine's (SNM) 59th Annual Meeting in Miami Beach, Fla., June 9-12, Cardinal Health will introduce new technology enhancements that make it possible for hospital nuclear medicine departments and imaging centers to seamlessly improve data integration and the overall efficiency of their operations.

8 Jun 2012

Medical imaging revenue market for CEE and Russia to reach $2.34 billion in 2015

Rising disease incidence and growing awareness about health issues will boost demand for medical imaging services across Central and Eastern Europe (CEE).

30 May 2012

TJU researchers to investigate Cu-64 imaging agent for prostate cancer

Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.

17 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Dopamine linked to willingness to work for a monetary reward

A new brain imaging study has shown that an individual’s willingness to work hard to earn money is strongly influenced by the chemistry in three specific areas of the brain. Researchers claim that this could have important implications for the treatment of attention-deficit disorder, depression, schizophrenia and other forms of mental illness characterized by decreased motivation.

3 May 2012

Human study suggests biological basis for individual differences in behavior

Whether someone is a "go-getter" or a "slacker" may depend on individual differences in the brain chemical dopamine, according to new research in the May 2 issue of The Journal of Neuroscience. The findings suggest that dopamine affects cost-benefit analyses.

2 May 2012

GE Healthcare, NXT2B partner to develop micro-scale radiotracer infrastructure

GE Healthcare, a unit of General Electric Company, and NXT2B, a privately owned venture capital company, today announced they have entered into a joint financing agreement with the goal of developing a micro-scale radiotracer infrastructure including cyclotron and PET tracer production.

20 Apr 2012

SBU to advance research and clinical care at National Pediatric MS Center

Stony Brook University has received a $2.5 million gift from Robert and Lisa Lourie to advance research and clinical care at the National Pediatric Multiple Sclerosis (MS) Center at Stony Brook Long Island Children's Hospital and to establish a new state-of-the-art imaging center at Stony Brook Medicine.

19 Apr 2012

Avid Radiopharmaceuticals receives FDA approval for Amyvid to treat AD

The U.S. Food and Drug Administration today approved Amyvid (Florbetapir F 18 Injection) a drug for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

11 Apr 2012

FDA approves scan to detect Alzheimer’s disease early

The test uses a chemical called florbetapir, known by the brand name Amyvid, which is a radioactive agent that tags clumps of a sticky substance called an amyloid. Amyloid proteins are hallmarks of Alzheimer's disease. The chemical, which costs $1,600 per dose, then is detected using a brain imaging technique called positron emission tomography, known as PET scans. For patients who already have some symptoms of cognitive decline, a positive scan suggests that moderate to frequent amyloid plaques are present in the brain, which is consistent with Alzheimer's disease.

9 Apr 2012

Scientists image process of consciousness after general anesthesia

Awakening from anesthesia is often associated with an initial phase of delirious struggle before the full restoration of awareness and orientation to one's surroundings. Scientists now know why this may occur: primitive consciousness emerges first. Using brain imaging techniques in healthy volunteers, a team of scientists led by Adjunct Professor Harry Scheinin, M.D. from the University of Turku, Turku, Finland in collaboration with investigators from the University of California, Irvine, USA, have now imaged the process of returning consciousness after general anesthesia.

5 Apr 2012

PET allows survival predictions in sarcoma after initial cycle of neoadjuvant chemo

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

3 Apr 2012

Systemic inflammation may contribute to depressive symptoms

New research published in the April issue of The Journal of Nuclear Medicine reveals that systemic inflammation causes an increase in depressive symptoms and metabolic changes in the parts of the brain responsible for mood and motivation. With this finding, researchers can begin to test potential treatments for depression for patients that experience symptoms that are related to inflammation in the body or within the brain.

3 Apr 2012

Dyax, GE Healthcare partner to develop and commercialize c-Met imaging peptides

GE Healthcare, a unit of GE, and Dyax Corp. today announced a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax.

2 Apr 2012

ImaginAb completes Series A financing

ImaginAb, Inc. a clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, today announced the completion of a Series A financing – led by Novartis Venture Funds.

27 Mar 2012

Scans reveal Williams syndrome-associated personality/temperament traits

A personality profile marked by overly gregarious yet anxious behavior is rooted in abnormal development of a circuit hub buried deep in the front center of the brain, say scientists at the National Institutes of Health. They used three different types of brain imaging to pinpoint the suspect brain area in people with Williams syndrome, a rare genetic disorder characterized by these behaviors.

21 Mar 2012

Adalimumab may decrease vascular inflammation in patients with psoriasis

A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could be associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease.

17 Mar 2012

Mount Sinai receives Le Foundation gift for psychiatric neuroimaging study

The Department of Psychiatry at Mount Sinai School of Medicine has received a $250,000 gift from The Iris & Junming Le Foundation to advance neuroimaging research conducted by young scientists in the early stages of their careers.

23 Feb 2012

Lawson Health Research Institute receives new hybrid imaging scanner

Imagine being able to detect Alzheimer's disease at its earliest stage and prescribe the proper medication to halt its progress. Imagine being able to evaluate the health of heart muscles and tissues after an attack and accurately prescribe treatment to prevent future heart failure. London is close to making these possibilities a reality with the installation of Canada's first whole body PET/MRI scanner at St. Joseph's Hospital, part of St. Joseph's Health Care London.

8 Feb 2012